A promotion for Managing Director of Bristol-Myers Squibb Australia and New Zealand, Anthony Mancini.
Mr Mancini is returning to North America to join the company's Commercial Leadership Team as Senior Vice President of the company's US Cardiovascular business.
"In this role, Anthony will be responsible for the cardiovascular business in the US, with a particular focus on ELIQUIS (apixaban), and will lead an organisation of over 1200 people as well as the alliance with Pfizer in the US," the company said in a statement.
Mr Mancini has headed the Australian and New Zealand business since September 2012. In that time, he has overseen the PBS launch of a number of products, including ELIQUIS for atrial fibrillation and YERVOY for advanced melanoma.
The company recently achieved Aon Hewitt Best Employer accreditation status for the third year in a row. It was the only pharmaceutical company accredited as a Best Employer in Australia and New Zealand.
Mr Mancini has also served on the Medicines Australia Board during his time in Australia.
His promotion means he has not renominated for the Board in the current election, creating an additional vacancy following the recently announced departures of two other managing directors who also served as Board members.
The company said it was yet to make an announcement on Mr Mancini's successor.
